Join our daily newsletter At The Bell to receive exclusive market insights
- Structural heart company Anteris Technologies (AVR) has filed a provisional application for a new patent related to its ADAPT technology
- ADAPT is a BioScaffold that reportedly re-engineers xenograft tissue into a pure collagen scaffold
- The new patent adds to the current patent family as well as sets new patent protections into the future for the ADAPT process
- Dubbed ADAPT 2.0, the new patent specifically applies to the sterilisation process that allows the safe transfer of product to manufacture of valves
- Anteris was down 4.13 per cent and is trading at $12.78 per share.
Structural heart company Anteris Technologies (AVR) has filed a provisional application for a new patent related to its ADAPT technology.
ADAPT is a BioScaffold that reportedly re-engineers xenograft tissue into a pure collagen scaffold.
The new patent adds to the current patent family as well as sets new patent protections for the future of the ADAPT process.
Dubbed ADAPT 2.0, the new patent specifically applies to the sterilisation process that allows the safe transfer of product to the manufacture of valves.
Commenting on this announcement is CEO Wayne Paterson.
“This new process opens up the potential for additional manufacturing sites for the company globally as volumes increase, as well as allowing the company to ramp up valve production (due to the extended shelf life before the manufacturing step),” Mr Paterson said.
“ADAPT 2.0 will allow expanded manufacturing capacity of DurAVR™ at additional sites by starting the process in our Australian facility and completing valve manufacture at our US facility, saving significant time and money in the process.
“This is important as we enter the expanded clinical trial phase and for commercialisation,” he concluded.
Anteris was down 4.13 per cent and is trading at $12.78 per share at 1:15 pm AEDT.
